TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16125994

Group type: EXPERIMENTAL
Intervention: Backpack loads of 0, 7.5, 10, 12.5 and 15% body weight
Number of subjects: 50

Group type: COMPARATOR
Intervention: Adolescent idiopathic scoliosis (AIS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Backpack loads (7.5% body weight) in AIS group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study: 11898510

Group type: EXPERIMENTAL
Intervention: Triptans (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified-care model for migraine management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive medical and psychologic evaluation for tension-type headaches
Number of subjects: 0
Study: 9579834

Group type: EXPERIMENTAL
Intervention: BCDT with IL-2/IFN-alpha
Number of subjects: 65

Group type: COMPARATOR
Intervention: BCDT alone
Number of subjects: 65
Study: 8037261

Group type: EXPERIMENTAL
Intervention: Intravenous sodium lactate infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study: 3378983

Group type: EXPERIMENTAL
Intervention: Trained endurance athletes (T)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untrained individuals (UT)
Number of subjects: 13
Study: 28958504

Group type: EXPERIMENTAL
Intervention: Rilotumumab plus epirubicin, cisplatin, and capecitabine
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo plus epirubicin, cisplatin, and capecitabine
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Rilotumumab
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 23030252

Group type: EXPERIMENTAL
Intervention: Pilocarpine (10 mg)
Number of subjects: 5
Study: 20801047

Group type: EXPERIMENTAL
Intervention: Preoperative proprioceptive training (TG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG)
Number of subjects: 0
Study: 19216936

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg, i.e., two sticks of Stay Alert gum) administered at 0100, 0300, 0500, and 0700 during nights 2, 3, and 4
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo administered at the same times as caffeine
Number of subjects: 18
Study: 17664481

Group type: EXPERIMENTAL
Intervention: Tumor sclerosis
Number of subjects: 158
Study: 15076260

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 62
Study: 11881131

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once-daily for four weeks, titrated to 80 mg if necessary
Number of subjects: 71

Group type: COMPARATOR
Intervention: Enalapril 10 mg once-daily for four weeks, titrated to 20 mg if necessary
Number of subjects: 71
Study: 9663917

Group type: EXPERIMENTAL
Intervention: Active therapy (n=16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7824673

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 2687135

Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes administered endotracheally in pre- and postoperative periods
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 259
Study: 31851093

Group type: EXPERIMENTAL
Intervention: 10-day dual therapy (esomeprazole 20 mg and amoxicillin 750 mg, q.i.d.)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 14-day dual therapy (esomeprazole 20 mg and amoxicillin 1000 mg, t.i.d.)
Number of subjects: 208
Study: 30866559

Group type: EXPERIMENTAL
Intervention: Days with asthma presentations exceeding four standard deviations from the mean (case days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Days with asthma presentations less than one standard deviation from the mean (control days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of epidemic thunderstorm asthma risk
Number of subjects: 0
Study: 28511713

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQAS)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 900
Study: 25886958

Group type: EXPERIMENTAL
Intervention: Arthroscopic osteochondroplasty with/without labral repair
Number of subjects: 220

Group type: COMPARATOR
Intervention: Arthroscopic lavage of the hip joint
Number of subjects: 220
Study: 23868885

Group type: EXPERIMENTAL
Intervention: Littmann 3200 electronic stethoscope
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Littmann Cardiology III acoustic stethoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Holtex Ideal acoustic stethoscope
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Comparison between Littmann 3200 and Littmann Cardiology III
Number of subjects: 100
Study: 22090660

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study: 19104814

Group type: EXPERIMENTAL
Intervention: Capecitabine (2,000 mg/(m(2) day) on days 1-14) and Irinotecan (250 mg/m(2) every 3 weeks)
Number of subjects: 29
Study: 16508400

Group type: EXPERIMENTAL
Intervention: Parecoxib and valdecoxib
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study: 15731605

Group type: EXPERIMENTAL
Intervention: 0.25% spinal ropivacaine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.25% spinal levobupivacaine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.25% spinal bupivacaine
Number of subjects: 97

Group type: COMPARATOR
Intervention: ropivacaine
Number of subjects: 97

Group type: COMPARATOR
Intervention: levobupivacaine
Number of subjects: 97

Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 97

Group type: COMPARATOR
Intervention: bupivacaine and levobupivacaine
Number of subjects: 97
Study: 12930013

Group type: EXPERIMENTAL
Intervention: Large middle meatal antrostomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Undisturbed maxillary ostium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 10193918

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study: 7852519

Group type: EXPERIMENTAL
Intervention: hGH replacement therapy (12.5 micrograms/kg BW, self-administered daily sc)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2094113

Group type: EXPERIMENTAL
Intervention: Etofenamate 10% cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral naproxen
Number of subjects: 60
Study: 728318

Group type: EXPERIMENTAL
Intervention: Oxyphenisatin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anthracene purgatives
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: (+)-norpseudoephedrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined preparation of (+)-norpseudoephedrine and senna
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30234848

Group type: EXPERIMENTAL
Intervention: OVRT test battery including metrics of saccades, smooth pursuit tracking, nystagmoid movements, vestibular function, and reaction time latencies.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OVRT test battery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects (n = 170)
Number of subjects: 50
Study: 28225674

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lanadelumab 400 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 24610803

Group type: EXPERIMENTAL
Intervention: Personal exposure measurements using a magnetic field dosimeter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distance to the bore of the MRI scanner
Number of subjects: 0
Study: 22534471

Group type: EXPERIMENTAL
Intervention: Nurse follow-up dietary intervention (NFDI) including a structured 8-week program with face-to-face consultation and fortnightly telephone follow-ups
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional care and attendance at a heart health dietary class
Number of subjects: 82
Study: 21898496

Group type: EXPERIMENTAL
Intervention: sorafenib 800 mg/day
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: sorafenib half dose
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: sorafenib therapy
Number of subjects: 296
Study: 20015433

Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbal medicine plus conventional treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo plus conventional treatment
Number of subjects: 28
Study: 16467013

Group type: EXPERIMENTAL
Intervention: Physician characteristics (e.g., professional orientation, location, and experience)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Patient factors (e.g., contact with drug subculture, appearance, employment status, social support, having children)
Number of subjects: 296
Study: 15583373

Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 3774

Group type: COMPARATOR
Intervention: Never smoked
Number of subjects: 3774
Study: 11058618

Group type: EXPERIMENTAL
Intervention: Selenium levels (highest quartile)
Number of subjects: 2071

Group type: COMPARATOR
Intervention: Low selenium levels
Number of subjects: 2071
Study: 9353692

Group type: EXPERIMENTAL
Intervention: Doxacurium administered by bolus injection
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Doxacurium administered by 10-min infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Doxacurium with Rtot model (bolus)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Doxacurium with Rtot model (infusion)
Number of subjects: 15
Study: 8385179

Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isocaloric control drink
Number of subjects: 21
Study: 2868039

Group type: EXPERIMENTAL
Intervention: Peri-incisional mezlocillin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Rectal metronidazole
Number of subjects: 140
Study: 29342506

Group type: EXPERIMENTAL
Intervention: DASH-Plus diet (coach-directed dietary advice, assistance with purchasing DASH-related foods $30/week, home delivery of food)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control diet (DASH diet brochure and debit card account $30/week to purchase foods)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Higher baseline serum UA levels
Number of subjects: 117
Study: 28554530

Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation (EMS) treatment, 3 times over a period of 1 week, 1-hour sessions each.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electrical Muscle Stimulation (EMS) treatment
Number of subjects: 24
Study: 26424212

Group type: EXPERIMENTAL
Intervention: SUA quartile III (281-420 mmol/L)
Number of subjects: 12677

Group type: EXPERIMENTAL
Intervention: SUA quartile IV (420-1640 mmol/L)
Number of subjects: 12677

Group type: EXPERIMENTAL
Intervention: Addition of SUA as a biomarker
Number of subjects: 12677
Study: 23865335

Group type: EXPERIMENTAL
Intervention: Reference preparation of oxaprozin enteric coated tablets (0.4 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Test preparation of oxaprozin enteric coated tablets (0.4 g)
Number of subjects: 20
Study: 21547496

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg (n=26)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19002650

Group type: EXPERIMENTAL
Intervention: Sertraline usual formulation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sertraline liquid oral concentrate (LOC) formulation
Number of subjects: 54
Study: 15964100

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 or 40 IU)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 61
Study: 12877701

Group type: EXPERIMENTAL
Intervention: Dual coil defibrillation lead system (group 1, n = 38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Single coil defibrillation lead system (group 2, n = 38)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (dual and single coil)
Number of subjects: 76
Study: 11461738

Group type: EXPERIMENTAL
Intervention: Propranolol (1.6 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Digoxin and diuretics
Number of subjects: 20
Study: 9923363

Group type: EXPERIMENTAL
Intervention: Implementing formative assessment and learning contracts
Number of subjects: 0
Study: 8091754

Group type: EXPERIMENTAL
Intervention: Live cold-adapted attenuated vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-virus inactivated trivalent vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All vaccines (including live and inactivated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revaccinated children with preexisting antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual influenza revaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine strains
Number of subjects: 0
Study: 3413454

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: No physiotherapy (Control)
Number of subjects: 30
Study: 31313331

Group type: EXPERIMENTAL
Intervention: High-intensity drinking (2+ times binge level)
Number of subjects: 2442

Group type: COMPARATOR
Intervention: Standard binge drinking (1 to 2 times binge level)
Number of subjects: 2442
Study: 29231342

Group type: EXPERIMENTAL
Intervention: Warm needling pretreatment (once a day) at specific acupuncture points for three months before embryo transfer, along with antibiotics and oral progesterone after ovulation.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group treated with antibiotics in the menstrual period and oral progesterone after ovulation.
Number of subjects: 56
Study: 25925226

Group type: EXPERIMENTAL
Intervention: HOME Plus intervention (community-based program with ten monthly sessions and five motivational calls)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: HOME Plus intervention (cooking with families, learning to eat healthfully, trying new recipes)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Attention-only control group (not explicitly detailed in the abstract)
Number of subjects: 81
Study: 23938154

Group type: EXPERIMENTAL
Intervention: Structured health promotion programme (physical activity and education programme) executed in five day-activity centres for eight months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group) in five other centres.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured health promotion programme (physical activity and education programme).
Number of subjects: 0
Study: 21766223

Group type: EXPERIMENTAL
Intervention: Mirror visual feedback from the less-impaired arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actual visual feedback from the two arms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mirror visual feedback from the impaired arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror visual feedback (general)
Number of subjects: 0
Study: 18551819

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine (Levobupivacaine group, n = 96)
Number of subjects: 186

Group type: COMPARATOR
Intervention: IV PCA morphine only (Morphine PCA group, n = 90)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine (Levobupivacaine group)
Number of subjects: 186

Group type: COMPARATOR
Intervention: IV PCA morphine only (Morphine PCA group)
Number of subjects: 186
Study: 16520410

Group type: EXPERIMENTAL
Intervention: 3 g/day of ginseng for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 52
Study: 12775894

Group type: EXPERIMENTAL
Intervention: Emla cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo occlusive dressing
Number of subjects: 12
Study: 10551577

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.25%, 1 ml/kg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bupivacaine (0.25%, 1 ml/kg)
Number of subjects: 81
Study: 8531998

Group type: COMPARATOR
Intervention: Carbimazole alone for 17 months
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Carbimazole plus T4 for 17 months and T4 alone for 18 months
Number of subjects: 111
Study: 1860289

Group type: EXPERIMENTAL
Intervention: Malarial chemoprophylaxis (300 mg chloroquine weekly for at least one year)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Non-chemoprophylaxis (not on regimen for at least one year)
Number of subjects: 92
Study: 6631350

Group type: EXPERIMENTAL
Intervention: Free visit with new physician
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reassignment to new physician providers
Number of subjects: 0
Study: 31123090

Group type: COMPARATOR
Intervention: Bedsheet only
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bedsheet and intravenous pole
Number of subjects: 28
Study: 31524681

Group type: EXPERIMENTAL
Intervention: High-grade gliomas with low FDG uptake
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-grade gliomas with high FDG uptake
Number of subjects: 12
Study: 29197371

Group type: EXPERIMENTAL
Intervention: Patient-focused intervention to improve communication and decision-making regarding clinical trial participation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician-focused intervention to improve communication and trial offers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-focused intervention to improve communication quality during clinical interactions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-focused intervention to enhance understanding of trials offered.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-focused intervention to increase actual enrollment in trials.
Number of subjects: 0
Study: 25839390

Group type: EXPERIMENTAL
Intervention: Integrative Muscular Movement Technique (IMMT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Swedish massage
Number of subjects: 38
Study: 23306815

Group type: EXPERIMENTAL
Intervention: Flowchart
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-flowchart
Number of subjects: 83
Study: 21664280

Group type: EXPERIMENTAL
Intervention: Psychosocial stress task (n=18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non‐stressful control procedure (n=20)
Number of subjects: 38
Study: 18715524

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 50 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16423208

Group type: EXPERIMENTAL
Intervention: Intravenous cisplatin therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intravenous OK432 therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination therapy with cisplatin and OK432
Number of subjects: 49
Study: 15052382

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1000 mg i.v.)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Sivelestat (0.20 mg/kg per h)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Immunoglobulin (5 g for 3 days)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872

Group type: COMPARATOR
Intervention: Sivelestat (0.004 mg/kg per h)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Control group for immunoglobulin
Number of subjects: 872
Study: 10902749

Group type: EXPERIMENTAL
Intervention: Short Form 36 (SF-36) modified health survey
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ) disability index
Number of subjects: 693

Group type: COMPARATOR
Intervention: RA severity measures (patient and physician global assessments, joint swelling and tenderness counts, global pain assessment)
Number of subjects: 693
Study: 8823657

Group type: EXPERIMENTAL
Intervention: FEV1 residual less than -1.2 L (optimal cut-off)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FEV1 and FEV1/FVC parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False-positive and false-negative decisions
Number of subjects: 0
Study: 1531318

Group type: EXPERIMENTAL
Intervention: Packing of the presacral space after suture of the pelvic peritoneum
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Suture of the pelvic peritoneum and perineal wound, leaving two drains through the perineum
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: No suture of the pelvic peritoneum, and primary closure of the perineal wound, leaving drains through the abdomen for physiological saline irrigation
Number of subjects: 102
Study: 6380858

Group type: EXPERIMENTAL
Intervention: Once-daily metoprolol (Betaloc tablets)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Twice-daily metoprolol (Betaloc Durules)
Number of subjects: 389
Study: 3524185

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 to 80 mmol/day orally)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Potassium-sparing diuretic amiloride
Number of subjects: 19
Study: 31364415

Group type: EXPERIMENTAL
Intervention: Roc>95 (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Roc50 (n=14)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (n=16)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 29759656

Group type: EXPERIMENTAL
Intervention: Emergency medicine residency training
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Self-reported health concerns
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Sources of stress
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Career satisfaction
Number of subjects: 766
Study: 27929346

Group type: COMPARATOR
Intervention: d-amphetamine 0 mg (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: d-amphetamine 1 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: d-amphetamine 2 mg
Number of subjects: 40
Study: 25045832

Group type: EXPERIMENTAL
Intervention: Probiotic-enriched foods or dietary supplement containing SYNBIO®
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 200
Study: 22512861

Group type: EXPERIMENTAL
Intervention: HDHK program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 53